Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKayleigh McCloskeyJAJames AriesVMVarun Mehra

Discussion

Loading...

Member takes

Overview

Prospective analysis shows improved survival in DDX41-mutated myeloid neoplasms post-transplant, suggesting effective HCT strategies.

Key Points

  • This analysis aims to assess outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms.
  • Evaluated 26 adult patients with DDX41-mutated myeloid neoplasms undergoing allogeneic HCT
  • Analyzed rates of acute and chronic graft-versus-host disease and survival endpoints
  • Used Kaplan-Meier method for estimating overall survival and relapse-free survival
  • Median one-year overall survival was 86.6% and three-year was 72.1%
  • Acute graft-versus-host disease occurred in 31.8% of evaluable patients
  • Nine patients experienced relapse after HSCT at a median time of 24 months

Cite This Study

McCloskey et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b5https://doi.org/10.1182/blood-2025-6083
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  2. 2DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre2025
  3. 3Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation2026
  4. 4Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study2025
  5. 5Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025